Company: TYRA
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0000950170-25-046124
Chunk: 212

Company: Tyra Biosciences, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1B
Chunk 212
---
 Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. 

    TYRA BIOSCIENCES, INC.

    /s/ Todd Harris, Ph.D.

    Todd Harris, Ph.D.President, Chief Executive Officer, and Director

Date: March 27, 2025

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. 

    Name
     
    Title
     
    Date

    /s/ Todd Harris, Ph.D.
     
    President, Chief Executive Officer and Director
     
    March 27, 2025

    Todd Harris, Ph.D.
     
    (principal executive officer)

    /s/ Alan Fuhrman
     
    Chief Financial Officer
     
    March 27, 2025

    Alan Fuhrman
     
    (principal financial and accounting officer)

    /s/ Adele M. Gulfo
     
     Director
     
    March 27, 2025

    Adele M. Gulfo

    /s/ Gilla Kaplan, Ph.D.
     
     Director
     
    March 27, 2025

    Gilla Kaplan, Ph.D.

    /s/ Melissa McCracken, Ph.D.
     
     Director
     
    March 27, 2025

    Melissa McCracken, Ph.D.

    /s/ Susan Moran, M.D., M.S.C.E.
     
     Director
     
    March 27, 2025

    Susan Moran, M.D., M.S.C.E.

    /s/ Robert More
     
     Director
     
    March 27, 2025

    Robert More

    /s/ S. Michael Rothenberg, M.D., Ph.D.
     
     Director
     
    March 27, 2025

    S. Michael Rothenberg, M.D., Ph.D.

    /s/ Jake Simson, Ph.D
     
     Director
     
    March 27, 2025

    Jake Simson, Ph.D.

    /s/ Rehan Verjee
     
     Director
     
    March 27, 2025

    Rehan Verjee

143